Boule Diagnostics Second Quarter 2025 Earnings: Misses Expectations

Boule Diagnostics (STO:BOUL) Second Quarter 2025 Results

Key Financial Results

• Revenue: kr129.3m (down 5.6% from 2Q 2024).
• Net loss: kr5.70m (loss widened by 256% from 2Q 2024).
• kr0.15 loss per share (further deteriorated from kr0.04 loss in 2Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Boule Diagnostics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are down 32% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Boule Diagnostics has 2 warning signs we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.